Tariff risks and opportunities for pharma manufacturers - European Pharmaceutical Review

The latest salvo in the emerging global tariff tiff has set its sights on the pharma sector.  Aiming to stabilize US drug supplies, tariffs may have the opposite effect while posing a number of key risks to pharma companies large and small.  Mitigating these supply chain, operational, business and financial risks will require measured yet nimble responses and out-of-the box thinking.  Leveraging advanced manufacturing technologies such as continuous manufacturing could help pharma companies mitigate tariff risk while seizing a competitive advantage.